Harrow Relaunches TRIESENCE®

by Business Wire • 2024/10/03 • 0 Comments

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. In commenting on the announcement, Mar

← Riassunto: Novaliq e Laboratoires Théa annunciano la sigla di una partnership e l’approvazione da parte della UE di Vevizye® (soluzione in collirio liquido allo 0,1% di ciclosporin)

Does One DME Treatment Have Edge in Reducing Hard Exudates? →

Post navigation